WASHINGTON (January 28)  -- Yesterday, the Centers for Medicare & Medicaid Services announced  the third round of drugs subject to Medicare price controls under the Inflation Reduction Act. The new government-set prices will affect medicines covered under both Medicare Part D and Medicare Part B and take effect in 2028.   Incubate's executive director, John Stanford, issued the following statement in response:   "The latest announcement from CMS represents a significant expan

WASHINGTON ( January 15 ) -- Today, President Trump unveiled  his "Great Healthcare Plan," including a proposal for Congress to codify Most Favored Nation  (MFN) drug pricing into law. This policy would import foreign government price controls into the U.S. market and threaten the innovation ecosystem responsible for delivering new cures and lifesaving treatments.    Incubate's executive director, John Stanford, issued the following statement in response to the announcement:

WASHINGTON ( January 12 ) -- Today, Incubate Policy Lab released insights from a survey of life sciences venture capital (VC) investors showing that policy -- not just scientific potential -- is playing an increasing role in how investors assess biotech opportunities. In other words, VCs aren't just watching the science; they're watching Washington.   The VCs surveyed invest in various companies, including early-stage startups and large, publicly traded firms. Respondents poi

2025 brought no shortage of new ideas in Washington to reshape how the United States pays for medicines. From Most Favored Nation  (MFN) proposals to executive actions and broader drug pricing reforms, the policy debate moved quickly, with major implications for patients, investors, and the future of biomedical innovation.  Throughout the year, Incubate stayed at the cutting edge of that dialogue, bringing a consistent focus to what matters most: protecting access today while